Introduction
============

*Chlamydia trachomatis* (serotypes D--K) are obligatory intracellular gram-negative bacteria that primarily infect the female cervix, urethra, and fallopian tubes. The majority of infection is asymptomatic and goes undetected, with an increased risk of pelvic inflammatory disease, and is the leading cause of ectopic pregnancy, tubal factor infertility,[@b1-ijwh-5-277]--[@b3-ijwh-5-277] and chronic pelvic pains.

In Saudi Arabia, the incidence of sexually transmitted infections is low compared with that in developed countries. Gonococcal and nongonococcal urethritis and genital warts have been reported frequently among Saudis, whereas AIDS, syphilis, and genital herpes are frequently reported among non-Saudis.[@b4-ijwh-5-277]

For diagnosis of chlamydia infection, cell culture of urogenital specimens has been considered the ideal method, although few laboratories could offer this, due to its cost and lack of experience in the cell culture technique. Accurate results depend on the proper sample taking, carrying, storage, and interpretation. Although culture is 100% specific for chlamydia (no false positives), there is a growing observation that culture is not 100% sensitive. The combination of 100% specificity and the ability to detect viable organisms makes culture the standard for legal applications such as for sexual assault.

With the availability of more rapid assays during the 1980s, many laboratories started to use enzyme-linked immunosorbent assay (ELISA) due to its lesser demands on cost, skills, and time required for obtaining the results. However, these tests were less sensitive, as detection of antibodies in a single serum sample has frequently been found in the absence of active infection.[@b5-ijwh-5-277] Despite the difficulty of differentiating between previous and current infections, the presence of chlamydia-specific antibody (immunoglobulin \[Ig\]A) is significantly associated with upper genital tract infection, particularly when the antibody titre is high.[@b6-ijwh-5-277],[@b7-ijwh-5-277] As sensitivity of the ELISA test is low, this can assist but cannot replace direct antigen detection or isolation of the organism by the culture technique.[@b8-ijwh-5-277]

Another widely used rapid simple test is enzyme immunoassay. It does not require any sophisticated equipment and it takes only 30 minutes to be completed. It is significantly less sensitive and specific than the laboratory-based tests. Reported sensitivities of rapid tests relative to the culture range from 52% to 85% for endocervical swabs, and their specificities are over 95%.[@b9-ijwh-5-277]--[@b11-ijwh-5-277] However, rapid tests are not recommended to be used in a low-prevalence population or for asymptomatic women, due to the potential for false positives. Their results should always be confirmed by a laboratory test.

More recent and very sensitive nucleic acid amplification techniques (NAATs), such as polymerase chain reaction and ligase chain reaction, have been used for detection of chlamydia genetic material DNA in cervical and urethral samples.[@b12-ijwh-5-277]

A further development is nucleic acid hybridization (DNA-Probe) tests, which also detect chlamydia genetic material DNA. These tests are very accurate but are not as sensitive as the NAATs. Other diagnostic tests include transcription-mediated amplification, which amplifies the ribosomal-RNA; strand displacement amplification; and direct fluorescent antibody tests. Papanicolaou smear is not an option for chlamydia screening, as it has poor sensitivity and poor specificity.

Sweden is known to have the best chlamydia screening program in the world.[@b13-ijwh-5-277] In the USA, the Centers for Disease Control and Prevention have supported a screening program since 1988.[@b14-ijwh-5-277] The phased implementation of a national chlamydia screening program in the UK offers screening for all sexually active women, using NAATs.[@b15-ijwh-5-277]

Several studies have reported a decline in chlamydia prevalence after early screening and proper treatment.[@b16-ijwh-5-277]--[@b18-ijwh-5-277] The best evidence to date about the effectiveness of screening for chlamydia infection in preventing pelvic inflammatory disease is a randomized controlled trial conducted in Seattle, USA.[@b19-ijwh-5-277] Two Swedish studies have supported its findings.[@b20-ijwh-5-277],[@b21-ijwh-5-277] Selective screening is more cost-effective than universal screening, although the latter may be indicated when prevalence of infection is high.[@b22-ijwh-5-277],[@b23-ijwh-5-277]

The present study aimed to screen Saudi infertile sexually active women in Jazan City, in the southwest region of Saudi Arabia, for possible *Chlamydia trachomatis* infection.

Patients and methods
====================

The study was conducted in Jazan General Hospital with the aid of laboratory facilities at the University of Jazan. The study covered a period of 1 year (from July 1, 2011 to June 30, 2012).

The study group included all Saudi married women of primary and secondary infertility, aged between 18 and 40 years, who attended the outpatient gynecology clinic at Jazan General Hospital for infertility examination during the period of study and agreed to participate (signed informed consent). The randomized control group included 100 Saudi married pregnant women who attended the outpatient obstetrics clinic for routine antenatal care during the period of study and agreed to participate (signed informed consent). Randomization was done using the Random Allocation Software^®^ (developed by Saghaei M, MD, Department of Anesthesia, Isfahan University of Medical Sciences, Iran) (Version 1.0, released on May 2004). Structured meetings were conducted with all recruited women, where they received an information sheet about the study and signed an informed consent.

Relevant medical records were reviewed for any possible present and past medical or surgical diseases. For a precise detection of chlamydia infection, two methods have been used for screening -- an indirect method for detection of chlamydia-specific IgG and IgA antibodies in the sera (ELISA), and a direct method for detection of chlamydia organism (McCoy \[Medac Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany\] cell culture). All participants' data and screening results were managed confidentially.

About 5 mL of venous blood was drawn from each participant for measurement of serum chlamydia IgG and IgA antibodies using a peptide-based enzyme-linked immunosorbent assay (IgG-pELISA Cat No 497/TMB, and IgA-pELISA Cat No 498/TMB Medac^®^, Wedel, Germany).

Each serum sample had a numerical code so that the clinical condition of the tested woman was unknown to the laboratory technician. All kits used in this study were of the same batch. Each kit contained 96 wells, and all tests were performed before their printed expiry dates. The manufacturer's instructions for test procedure were followed when performing the assays. The kits, microplates, controls, buffers, diluent, conjugate, 3,3′,5,5′-tetramethylbenzidine substrate, and stop solution were stored at 4°C and allowed to stand for 1 hour at room temperature before use. Results were interpreted according to the manufacturer's instructions, issuing a negative, equivocal, or positive result.

The intensity of the color is proportional to the concentration (titer) of the specific antibody in the sample. Cut-off values were calculated according to the manufacturer's instructions. Samples with optical density values located within the gray zone were retested again after 2 weeks in order to determine a titre change. Results remaining in the gray zone were considered negative.

The staff nurse of the outpatient clinic and two general practitioners were taught how to collect endocervical and urethral specimens. We used a cyto-brush (which collects more columnar cells than cotton-tipped swabs). The brush was inserted into the cervical os beyond the squamocolumnar junction 1--2 cm deep, rotated, and removed without touching the vaginal mucosa. The urethral swab was inserted 1 cm into the urethra, rotated once prior to removal, and placed in a separate tube of 2-sucrose-phosphate culture-transport medium. The examined women were instructed not to urinate within the previous hour (as urination washes out the infected columnar cells).

All collected samples were transported on wet ice to the laboratory of the university within 12 hours of collection. Strict adherence to the standard techniques of collecting specimens has biased the findings toward screening outcomes. As *Chlamydia trachomatis* is an obligatory intracellular pathogen, a specimen that lacks endocervical cells is discarded, as it will greatly increase the probability of a false negative result.

Specimens were inoculated into coverslip cultures of McCoy cells treated with cycloheximide. The inoculums were centrifuged for 1 hour. We used one-dram shell vials (more sensitive than multiwells). Inoculated cultures were incubated at 37°C for 3 days, washed, fixed in methanol, stained with Giemsa, (Medac Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany) and screened by dark-ground microscopy for possible intracytoplasmic inclusion bodies. Universal precautions were followed when handling such risky specimens, and all our laboratory workers were vaccinated against the hepatitis B virus earlier.

After the screening reports were collected, all participants were informed about their test results and the implications were discussed with the staff nurse. Any woman with a positive result was referred to the clinic for treatment with a notification letter for her husband to be tested and treated.

The collected clinical and laboratory data were stored on Microsoft^®^ Excel spreadsheets for Windows and then analyzed by suitable statistical methods using the StatsDirect^®^ Statistical Software (Version 2.7.9, released on July 9, 2012, StatsDirect Ltd, Cheshire, UK). The data were double-checked carefully during the process of collection, transcription, and computer inputting. No missing data were encountered. For testing significance, *t*-test and Yates-corrected χ^2^ test with Fisher exact at a confidence interval (CI) of 95% and a significance level of 5% were used. A finding was considered of statistical significance if *P*-value \< 0.05.

Results
=======

The rate of *Chlamydia trachomatis* infection among Saudi infertile women was higher than its rate among the Saudi fertile women ([Table 1](#t1-ijwh-5-277){ref-type="table"} and [Figure 1](#f1-ijwh-5-277){ref-type="fig"}).

The mean age of Saudi infertile women enrolled in this study as the study group was 26.4 ± 4.8 years. Women aged less than 25 years (276 women) had an infection rate of 7.81%, whereas those aged between 25 and 40 years (364 women) had an infection rate of 7.19% ([Figure 2](#f2-ijwh-5-277){ref-type="fig"}). This was not of statistical significance (CI 0.97--2.42, odds ratio \[OR\] 1.53, *P*-value = 0.0581).

Most of the Saudi infertile women had primary infertility (425 women) with an infection rate of 11.72%, whereas 215 women had secondary infertility with an infection rate of 3.28% ([Table 2](#t2-ijwh-5-277){ref-type="table"} and [Figure 3](#f3-ijwh-5-277){ref-type="fig"}).

The mean infertility duration for the study group was 3.28 ± 1.73 years. Cases with infertility duration less than 5 years were 498 women with an infection rate of 12.5%, whereas those with infertility duration longer than 5 years were 142 women with an infection rate of 2.5%. This finding was not of statistical significance (CI 0.84--2.86, OR = 1.51, *P*-value = 0.1832).

Among Saudi infertile women, a past history of sexually transmitted infection was mentioned by 165 women (25.78%), whereas 70 women (10.94%) reported a previous pelvic surgery. A history of a new husband in the preceding year was mentioned by 47 women (7.34%), whereas 23 women (3.59%) reported a past use of an intrauterine contraceptive cupper-T device.

Most women of the study group were asymptomatic (475 women) with an infection rate of 11.72%, whereas 165 women were symptomatic with an infection rate of 3.28% ([Figure 4](#f4-ijwh-5-277){ref-type="fig"}). This finding was not of statistical significance (CI 0.75--2.28, OR = 1.29, *P*-value = 0.3777).

Inquiry revealed a complaint of painful micturition in 115 women (17.97%), vaginal discharges in 98 women (15.31%), pelvic pains in 96 women (15.0%), irregular uterine bleeding in 47 women (7.34%), postcoital bleeding in 27 women (4.22%), and urethral discharge in three women (0.47%). On pelvic examination the signs were muco-purulent cervicitis in 224 women (35.0%), cervical friability in 132 women (20.63%), and hypertrophic cervix in 56 women (8.75%).

The rate of detection of *Chlamydia trachomatis* infection among infertile women using the ELISA test was 9.84%, whereas it was 12.03% using the culture technique ([Tables 3](#t3-ijwh-5-277){ref-type="table"} and [4](#t4-ijwh-5-277){ref-type="table"}, [Figure 5](#f5-ijwh-5-277){ref-type="fig"}). This finding was not of statistical significance (CI 0.55--1.15, OR = 0.798, *P*-value = 0.2443). Lastly, a predictive analysis for the screening tests used in this study was done using the StatsDirect^®^ Statistical Software ([Table 5](#t5-ijwh-5-277){ref-type="table"}).

Discussion
==========

*Chlamydia trachomatis* infection is a worldwide-distributed sexually transmitted infection. Prevalence of infection is difficult to estimate without screening, as most of the cases are asymptomatic. Although 929,462 cases of chlamydia infection were reported in the USA, according to the Centers for Disease Control and Prevention, in 2004,[@b14-ijwh-5-277] the actual number of cases is thought to be more than 2.8 million per year.[@b24-ijwh-5-277] According to the World Health Organization, new cases of chlamydia infection have been estimated globally to be 92 million.[@b25-ijwh-5-277] Both health and economic consequences of infection are serious; thus, prevention and early detection are essential.

The findings of this study highlight the need for chlamydia screening programs, as the prevalence of infection among Saudi infertile women in Jazan City, Saudi Arabia, is high (15.0%).

Sociodemographic risk factors for infection include young age,[@b26-ijwh-5-277],[@b27-ijwh-5-277] an urban setting and low income,[@b28-ijwh-5-277] having multiple sexual partners[@b29-ijwh-5-277] or an infected partner,[@b30-ijwh-5-277] nulliparity,[@b31-ijwh-5-277] and irregular use of barrier contraceptives or using oral contraceptive pills.[@b32-ijwh-5-277]

Due to local cultural and social constraints, our study excluded Saudi women aged less than 18 years. Consequently, direct comparison on chlamydia prevalence cannot be made precisely with western studies that include younger women (aged 15--19 years).[@b14-ijwh-5-277] Moreover, unmarried Saudi women were excluded from the present study, as the management of any positive cases would create both legal and social problems. Furthermore, routine inquiries about number of sexual partners is not realistic in an Islamic community.

In our study, the rate of infection was 7.81% for Saudi infertile women aged 18 to less than 25 years. This rate-age association is largely relating to the higher level of sexual activity among young women, whose squamocolumnar junction of the cervix still presents on ectocervix (cervical ectopy), which provides a large target area for infection.[@b33-ijwh-5-277] That is why age is used in many countries as a primary determinant for selective chlamydia screening programs.[@b34-ijwh-5-277]

The prevalence of chlamydia infection among asymptomatic healthy-looking Saudi women is 8.5% in Riyadh City,[@b35-ijwh-5-277] whereas it is 4.0% in our study in Jazan City, Saudi Arabia.

In this study, positive chlamydia was seen in 75 women out of 425 (17.65%) with primary infertility, and in 21 women out of 215 (9.77%) with secondary infertility. In an Indian study, positive chlamydia was seen in 20 women out of the 74 (27.03%) with primary infertility, and in eleven women out of the 36 (30.56%) with secondary infertility.[@b36-ijwh-5-277]

Although chlamydia infection is not yet a fully reportable infectious disease in Saudi Arabia, sera from patients who attended our clinic in Jazan was 9.06% positive for IgG antibodies and 5.0% positive for IgA antibodies. In Makkah City, chlamydia IgG antibodies were detected in 8.7% of pregnant Saudi women,[@b37-ijwh-5-277] whereas in our study, IgG antibodies were detected in only 4.0%.

This study is considered the first to screen Saudi infertile women for *Chlamydia trachomatis* infection as a possible causative factor for their infertility. Lack of chlamydia screening among Saudi women might result from a lack of awareness of the high rate of infection among young asymptomatic women and its serious late complications.

As there is a high prevalence of chlamydia infection among Saudi infertile women (evident in this study) and a high relationship between chlamydia infection and tubal factor infertility (evident in literature), it is mandatory to screen all Saudi infertile women for *Chlamydia trachomatis* at the start of their infertility examination prior to any invasive procedure.

The limitations of data surveyed in this study include its restriction to the geographic boundaries of Jazan City, to the time frame of 1 year, and to a specific target risk group (Saudi infertile women). There are several questions needed for further research, such as the prevalence of *Chlamydia trachomatis* infection among the general population in Saudi Arabia, the cost-effectiveness of selective versus universal screening programs, and the effect of a screening program in reducing the rate of infertility.

Conclusion
==========

The prevalence of *Chlamydia trachomatis* infection among Saudi infertile women at Jazan City, Saudi Arabia, is high (15.0%). This finding calls for a national screening program for the early detection of *Chlamydia trachomatis* infection among infertile couples in Saudi Arabia.

The ELISA test seems to be a good alternative to the culture method for screening purposes. It is simple and relatively cheap compared with the McCoy cell culture technique. It has a high specificity (100%) and a high negative predictive value (94.28%).
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###### 

Prevalence of *Chlamydia trachomatis* infection among Saudi women (cases versus controls)

  ----------------------------------------------------------------------------------------------------------------------------
  Screening results   Cases (infertile women)\   Controls (fertile women)\   Fisher exact 95% CI   *P*-value   OR       
                      n = 640                    n = 100                                                                
  ------------------- -------------------------- --------------------------- --------------------- ----------- -------- ------
  Infected            96 (15.0%)                 4 (4.0%)                    1.54                  16.21       0.0015   4.24

  Not infected        544 (85.0%)                96 (96.0%)                                                             
  ----------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CI, confidence interval; n, number of women; OR, odds ratio; *P*, significance level.

###### 

Prevalence of *Chlamydia trachomatis* infection among Saudi infertile women (primary versus secondary infertility)

  Screening results   Infertile cases (study group)   Fisher exact 95% CI   *P*-value   OR              
  ------------------- ------------------------------- --------------------- ----------- ------ -------- ------
  Infected            75 (11.72%)                     21 (3.28%)            1.16        3.49   0.0096   1.98
  Not infected        350 (54.69%)                    194 (30.31%)                                      

**Abbreviations:** CI, confidence interval; n, number of women; OR, odds ratio; *P*, significance level.

###### 

Interpretation of enzyme-linked immunosorbent assay test results

  IgG   IgA   Test interpretation                                          No of cases
  ----- ----- ------------------------------------------------------------ -------------
  \+    \+    Positive *Chlamydia trachomatis* infection                   27
  \+    −     Past *Chlamydia trachomatis* infection                       19
  −     \+    Early *Chlamydia trachomatis* infection                      3
  −     ?     Possible early *Chlamydia trachomatis* infection             0
  ?     −     Possible past *Chlamydia trachomatis* infection              7
  \+    ?     Past with possible early *Chlamydia trachomatis* infection   5
  ?     \+    Early with possible past *Chlamydia trachomatis* infection   2
  −     −     Negative *Chlamydia trachomatis* infection                   577

**Abbreviations:** Ig, immunoglobulin; +, positive; −, negative; ?, equivocal.

###### 

Comparing results of screening tests (Cat.No. 497/TMB and Cat.No. 498/TMB, Medac Gesellschaft für klinische Spezialpräparate mbH Geschäftseinheit Diagnostik, Wedel, Germany) (ELISA versus culture)

  Screening test       Positive   Equivocal   Negative
  -------------------- ---------- ----------- ----------
  IgG p-ELISA          51         9           580
  IgA p-ELISA          32         5           603
  McCoy cell culture   77         0           563

**Abbreviations:** ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin.

###### 

Prediction analysis of screening tests (Cat.No. 497/TMB and Cat.No. 498/TMB, Medac Gesellschaft für klinische Spezialpräparate mbHGeschäftseinheit Diagnostik, Wedel, Germany) (ELISA versus culture)

  Parameter     ELISA    McCoy cell culture
  ------------- -------- --------------------
  Sensitivity   65.62%   80.21%
  Specificity   100.0%   100.0%
  PPV           100.0%   100.0%
  NPV           94.28%   96.63%

**Abbreviations:** ELISA, enzyme-linked immunosorbent assay; NPV, negative predictive value; PPV, positive predictive value.
